Focus on validating Exosome delivery technology platform
Cash runway extended into 2024
Headcount reduced by 40%

19 January 2023: ReNeuron Group plc (AIM: RENE), a UK-based R&D organisation focused on stem-cell derived exosome delivery technologies, announces that further to the announcement of 3 January 2023, the Company has undertaken a restructuring of the business. Headcount has been reduced by 40%, the overall variable costs of the business lowered and, as a result, the cash runway now extends into 2024 with all resources being directed towards generating in vivo data and validating the Company’s exosome delivery technology platform CustomEX™.

Read more…

 

Back